Vyxeos Approval History
Vyxeos (cytarabine and daunorubicin liposome injection) is a liposomal combination of cytarabine, a nucleoside metabolic inhibitor, and daunorubicin, an anthracycline topoisomerase inhibitor, indicated for the treatment of adults with newly-diagnosed therapy-related
acute myeloid leukemia (t-AML) or AML with myelodysplasia-related
changes (AML-MRC).
Development History and FDA Approval Process for Vyxeos
| Date | Article |
|---|
| Aug 3, 2017 |  FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia |
| May 31, 2017 | Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status |
| Apr 3, 2017 | Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia |
| Oct 3, 2016 | Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017 |
| May 19, 2016 | Celator Pharmaceuticals Announces Vyxeos Granted Breakthrough Therapy Designation |
| Mar 14, 2016 | Celator Announces Phase 3 Trial for Vyxeos™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival |
| Dec 11, 2012 | Celator Pharmaceuticals Announces Data on the Effects of CPX-351 in High Risk AML Presented at the ASH Annual Meeting |
| Jun 5, 2012 | Celator Pharmaceuticals Announces Presentations of Positive Survival Analyses from CPX-351 Studies at ASCO Annual Meeting |
| Dec 12, 2011 | Celator Pharmaceuticals and the Leukemia & Lymphoma Society Announce Positive Data from Phase 2b Study of CPX-351 at the American Society of Hematology Annual Meeting |
| Dec 7, 2010 | Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting |
| Jun 7, 2010 | Celator Pharmaceuticals Announces Data on Remissions With CPX-351 Following Induction Failure |
| May 3, 2010 | Celator Pharmaceuticals Announces Positive Data From Phase 2 Study of CPX-351 in Acute Myeloid Leukemia |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
